In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Response to cardiac resynchronization therapy is present across all stages of chronic kidney disease

Session Rapid Fire 5 - Non-pharmacological treatments: beyond conventional

Speaker Jozine Ter Maaten

Congress : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Resynchronization Therapy
  • Session type : Rapid Fire Abstracts
  • FP Number : 1420

Authors : J M Ter Maaten (Groningen,NL), P Martens (Genk,BE), AH Maass (Groningen,NL), K Damman (Groningen,NL), M Dupont (Genk,BE), W Mullens (Genk,BE)

J M Ter Maaten1 , P Martens2 , AH Maass1 , K Damman1 , M Dupont2 , W Mullens2 , 1University Medical Center Groningen - Groningen - Netherlands (The) , 2Hospital Oost-Limburg (ZOL), Department of Cardiology - Genk - Belgium ,


Limited data is available on the effect of chronic kidney disease (CKD) on the response to cardiac resynchronization therapy (CRT) as these patients are often excluded from trials.

We therefore aimed to assess the effect of CRT on renal function, reverse remodeling and outcome across all stages of CKD in a large patient population of CRT recipients.

798 consecutive heart failure (HF) patients undergoing CRT implantation between October 2008 and September 2016 were retrospectively evaluated. Renal function was available at baseline and 6 months following CRT. Remodeling based on left ventricular end systolic volume (LVESV)/left ventricular ejection fraction (LVEF) and clinical outcome was assessed using a combined endpoint of all-cause mortality and HF hospitalization.

Median baseline eGFR was 62.8 [43.6-77.8] ml/min/1.73m2. 33.6% of patients were in CKD stage 3, 11.0% in stage 4, and 1.1% in stage 5. At 6 months, compared with CKD stage 1-2, renal function improved among CKD stage 3-5 patients (P<0.001). LVEF and LEVSV improved across all CKD stages, however patients with CKD stage 1-2 exhibited a greater degree of improvement in LVEF (median 15% vs. 10%, P<0.001) and LVESV (median -37.2% vs. -29.9%, P<0.001) compared to patients with CKD stage 3-5. Despite a greater degree of reverse remodeling in CKD stage 1-2, the most accurate cutoff of remodeling predicting good clinical outcome was lower for patients with CKD stage 3-5, respectively 5.5% vs. 9.5% (LVEF), and -6.67% vs. -12.41% (LVESV).

CRT results in reverse remodeling across all stages of CKD, although to a lesser extent in patients with renal dysfunction. However, patients with CKD derive benefit on outcome at a lesser degree of remodeling. Secondly, CRT results in stabilization of renal function in patients with CKD stage 3-5.

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are